Tuesday 24 November 2015

The Monday Night Muse - November 24 2015

If you want to know what’s going on in the world, there are places that will tell you the truth, not paint you a picture, maintain the status quo or be part of any international/inter-business synergy.

This is one of those places.

Stories, truths and angles that you need to know and have probably been sheltered from by the powers that be or your own search bubble.
  
Despite the political controversy surrounding medical marijuana use, research has begun to emerge showing that a component of this plant known as cannabidiol (CBD), and which does not have the controversial psychoactive properties associated with tetrahydrocannabinol (THC), may have a wide range of therapeutic applications, including treating conditions that are refractory to conventional drug-based approaches.

One such condition is Parkinson's disease, to which there is, at present, no effective conventional treatment. In fact, the primary treatment involves dopamine increasing drugs that also increase a neurotoxic metabolite known as with 6-hydroxy-dopamine, and which therefore can actually accelerate the progression of the disease. This is why natural alternatives that are safe, effective, and backed up by scientific evidence, are so needed today. 

Thankfully, preclinical research on cannabidiol has already revealed some promising results, including two studies in animal models of Parkinson's disease (PD) assessing its neuroprotective properties:
"In the first one, Lastres-Becker et al. (2005) showed that the administration of CBD counteracted neurodegeneration caused by the injection of 6-hydroxy-dopamine in the medial prosencephalic bundle, an effect that could be related to the modulation of glial cells and to antioxidant effects (Lastres- Becker et al., 2005). In the next year, Garcia-Arencibia et al. (2007) tested many cannabinoid compounds following the lesion of dopaminergic neurons in the substantia nigra with 6-hydroxy-dopamine and found that the acute administration of CBD seemed to have a neuroprotective action; nonetheless, the administration of CBD one week after the lesion had no significant effects (Garcia-Arencibia et al., 2007). This study also pointed to a possible antioxidant effect with the upregulation of  mRNA of the enzyme Cu-Zn-superoxide dismutase following the administration of CBD."
In addition to these animal studies, the following three human clinical trials have been conducted to evaluate cannabidiol's neuroprotective effects.

No comments:

Post a Comment